For Stealth BioTherapeutics Corp [MITO], Analyst sees a rise to $9. What next?


Stealth BioTherapeutics Corp [NASDAQ: MITO] traded at a high on 05/03/22, posting a 6.04 gain after which it closed the day’ session at $0.29. The company report on May 2, 2022 that STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression .

Categorical improvement in LLVA, with >15% of elamipretide-treated patients gaining 2+ lines of vision at Week 48.

The results of the trading session contributed to over 4394078 shares changing hands. Over the past one week, the price volatility of Stealth BioTherapeutics Corp stands at 23.22% while the volatility over the past one month is 14.73%.

The market cap for MITO stock reached $19.65 million, with 59.09 million shares outstanding and 8.55 million shares in the current float. Compared to the average trading volume of 276.18K shares, MITO reached a trading volume of 4394078 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Stealth BioTherapeutics Corp [MITO]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MITO shares is $3.03 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MITO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Stealth BioTherapeutics Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 14, 2020. The new note on the price target was released on April 02, 2020, representing the official price target for Stealth BioTherapeutics Corp stock. Previously, the target price had yet another drop from $21 to $5, while H.C. Wainwright kept a Neutral rating on MITO stock.

How has MITO stock performed recently?

Stealth BioTherapeutics Corp [MITO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.57. With this latest performance, MITO shares dropped by -56.01% in over the last four-week period, additionally sinking by -73.91% over the last 6 months – not to mention a drop of -75.64% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MITO stock in for the last two-week period is set at 22.07, with the RSI for the last a single of trading hit 17.13, and the three-weeks RSI is set at 26.81 for Stealth BioTherapeutics Corp [MITO]. The present Moving Average for the last 50 days of trading for this stock 0.5664, while it was recorded at 0.3625 for the last single week of trading, and 0.9449 for the last 200 days.

Stealth BioTherapeutics Corp [MITO]: Deeper insight into the fundamentals

Stealth BioTherapeutics Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.

Insider trade positions for Stealth BioTherapeutics Corp [MITO]

Positions in Stealth BioTherapeutics Corp stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 6 institutional holders increased their position in Stealth BioTherapeutics Corp [NASDAQ:MITO] by around 54,270 shares. Additionally, 6 investors decreased positions by around 32,114 shares, while 5 investors held positions by with 822,049 shares. The mentioned changes placed institutional holdings at 908,433 shares, according to the latest SEC report filing. MITO stock had 4 new institutional investments in for a total of 47,758 shares, while 2 institutional investors sold positions of 19,902 shares during the same period.